Want to see SE:BIOEX full AI Analyst Report?

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)82.14K

Market Cap

kr123.76M

Enterprise Valuekr90.32M

Total Cash (Recent Filing)kr3.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.81

Next Earnings

Aug 21, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding47,601,730

10 Day Avg. Volume104,394

30 Day Avg. Volume82,137

Financial Highlights & Ratios

PEG Ratio0.46

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.37

Revenue Forecast (FY)kr2.34M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt balance sheet materially lowers refinancing and interest-rate risk and gives management structural financing flexibility over the next 2-6 months. This durability improves the company’s ability to pursue partnerships or raise equity from a position of lower leverage, helping sustain operations while technology commercialization progresses.

Position In Industrial Biotech/biorefineryBioextrax operates in secularly growing markets for sustainable ingredients and bioprocessing. Structural demand for renewables and circular-economy inputs supports long-term addressable market expansion, increasing the odds that validated processes and products can secure multi-year commercial contracts or licensing deals.

Diversified Commercial Model (sales, Licensing, R&D Services)A multi-channel business model provides durable paths to revenue: product sales, licensing, and contracted R&D can generate different margin profiles and contract structures. If the company converts process IP into licenses or long-term service agreements, this can create recurring or milestone-driven revenue beyond one-off product sales.

Bears Say

Negative Gross ProfitPersistent negative gross margins indicate the core processes are not currently economically viable at scale. Without durable improvement in unit economics or lower cost inputs, the company cannot sustainably scale product sales or realize attractive licensing margins, making long-term profitability uncertain.

Consistent Negative Operating And Free Cash FlowChronic negative cash generation and an accelerating 2025 cash burn force reliance on external funding. Over the medium term this raises dilution risk, constrains R&D or commercialization investments, and can delay scaling even if technology milestones are achieved, undermining strategic plans.

Declining Equity And Negative Returns On EquityOngoing losses that erode equity signal structural capital destruction and reduce the cushion for operational setbacks. Negative ROE over multiple years impairs shareholder value and limits access to non-dilutive capital, increasing dependence on dilutive financing or unfavorable partnership terms.

Bioextrax AB News

85X0 Earnings this Week: How Will it Perform?

Bioextrax AB (85X0) is scheduled to report 1st quarter earnings on 05/14/2026. Regarding Q1 estimates, Wall Street analysts...

2M ago

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

5M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr123.76M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 29 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on May 20, 2026. The company reported -kr0.09 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.01.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.09.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 47,601,730 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.09 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 11.2%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.